Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Mirum Pharmaceuticals Inc. (MIRM)

20.5   1.23 (6.38%) 10-01 16:04
Open: 19.12 Pre. Close: 19.27
High: 20.72 Low: 19.12
Volume: 82,837 Market Cap: 521M
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 29 full-time employees. The firm is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The firm initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company has commenced enrollment in the Phase III clinical trial in PFIC and also planning to initiate a Phase III clinical trial in ALGS. The firm is developing volixibat for the treatment of adult patients with cholestatic liver diseases and expect to initiate Phase II clinical trials. In addition to data from ongoing clinical trials of maralixibat.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 19.841 - 19.943 19.943 - 20.02
Low: 18.492 - 18.595 18.595 - 18.674
Close: 19.104 - 19.28 19.28 - 19.415

Technical analysis

as of: 2020-10-01 3:36:27 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 27.58     One year: 31.52
Support: Support1: 18.14    Support2: 15.09
Resistance: Resistance1: 23.61    Resistance2: 26.99
Pivot: 19.87
Moving Average: MA(5): 19.44     MA(20): 20.06
MA(100): 20.21     MA(250): 16.39
MACD: MACD(12,26): -0.77     Signal(9): -0.80
Stochastic oscillator: %K(14,3): 38.30     %D(3): 29.16
RSI: RSI(14): 48.90
52-week: High: 28.31  Low: 6.51  Change(%): 90.4
Average Vol(K): 3-Month: 7014  10-Days: 6442

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
MIRM has closed below upper band by 33.7%. Bollinger Bands are 12.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 11 Sep 2020
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Valdosta Daily Times

Fri, 11 Sep 2020
Mirum Pharmaceuticals to Present at Investor Conferences in September - Rome News-Tribune

Tue, 01 Sep 2020
Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program - Yahoo Finance

Sat, 29 Aug 2020
Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020 - Business Wire

Fri, 07 Aug 2020
Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference - Yahoo Finance

Thu, 06 Aug 2020
Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates - Business Wire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 25
Shares Float (M) 6
% Held by Insiders 10.32
% Held by Institutions 73.60
Shares Short (K) 606
Shares Short P. Month (K) 607

Stock Financials

EPS -9.330
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 6.480
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -3.146
Qtrly Earnings Growth
Operating Cash Flow (M) -64
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -2.20
PEG Ratio
Price to Book value 3.16
Price to Sales
Price to Cash Flow -8.10

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.